The Patent Playbook Your Lawyers Won’t Write: The Complete Framework for Protecting Drug Revenue
A playbook for IP teams, portfolio managers, and R&D leads — from Paragraph IV mechanics and biosimilar patent dance tactics […]
Fix the Formula to Win the Generic Race: Overcoming Formulation Challenges in Generic Drug Development
The business of generic drug development is often misunderstood as a simple exercise in duplication. For many years, we operated
CDMO Price Benchmarking: Unlocking Market Domination Through Strategic Manufacturing Partnerships
How commercial manufacturing costs actually get built, what drives them, how CDMOs protect their pricing through IP assets, and what
Who Owns the AI-Discovered Drug? The Patent Ownership Guide Pharma IP Teams Need Now
The patent system did not anticipate generative chemistry. When Congress codified the requirement that inventors be ‘natural persons’ in 35
Who Owns the AI-Discovered Drug? The Patent Ownership Guide Pharma IP Teams Need Now Read Post »
MRAs That Actually Work: The Regulatory Fast-Track Every Generic Drug Team Needs to Map Now
A deep-dive reference for pharma IP teams, portfolio managers, regulatory strategists, and institutional investors tracking generic market entry timelines.
Specialty Generics: The $167B IP Playbook Pharma Analysts Need Now
1. What Are Specialty Generics — and Why the Definition Matters Defining the Asset Class With Precision The term ‘specialty
Specialty Generics: The $167B IP Playbook Pharma Analysts Need Now Read Post »
Precision Medicine Patent Strategy: The Complete IP Playbook for Pharma Portfolio Dominance
Key Takeaways (Top-Line Summary) Section I: What Precision Medicine Actually Is — and Why Its IP Complexity Is Unmatched Precision
Generic Drug Reverse Engineering: The Complete Analyst’s Guide to Deformulation, IP Strategy, and ANDA Approval
1. Why Deformulation Is a Patent Strategy Weapon Reverse engineering a branded drug is not simply a chemistry exercise. It
Who Owns the AI-Designed Drug? The Patent, Valuation, and IP Strategy Guide Pharma Needs Now
A technical reference for pharma IP counsel, portfolio managers, R&D strategy leads, business development teams, and institutional investors with exposure
